NMD Pharma A/S: Financial statements 2024
CVR: 36899069
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
NMD Pharma A/S (CVR 36899069) has filed annual accounts for 2024. In 2024, the company reported a gross profit of EUR -27,874,344 and a net result of EUR -32,253,700 compared with EUR -22,401,436 the year before. Equity in the 2024 report amounted to EUR 35,394,591. The solvency ratio was 89.8%. The company had 36 employees in the financial year.
- Gross Profit
- EUR -27,874,344
- Profit/Loss
- EUR -32,253,700
- Equity
- EUR 35,394,591
- Total Assets
- EUR 39,393,694
- Employees
- 36
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -27.9 mio. EUR | -32.3 mio. EUR | 35.4 mio. EUR | 36 |
| 2023 | - | -19.2 mio. EUR | -22.4 mio. EUR | 42.7 mio. EUR | 31 |
| 2022 | - | -9.5 mio. EUR | -12.3 mio. EUR | 25.1 mio. EUR | 26 |
| 2021 | - | -11 mio. EUR | -13.6 mio. EUR | 2.6 mio. EUR | 26 |
| 2020 | - | -7.9 mio. EUR | -9.9 mio. EUR | 9.2 mio. EUR | 22 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
NMD Pharma A/S has published its annual report for 2023. Gross profit came to DKK -19,182,079, and the net result was DKK -22,401,436.
About NMD Pharma A/S
NMD Pharma A/S is a Danish company of the type Aktieselskab based in Aarhus N, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named NMD Pharma ApS. The management consists of Thomas Holm Pedersen. The board consists of Michael Thomas Heffernan (chair), Anja Ulrike Harmeier, Christian Ellebæk Elling and Ivan Andreevich Burkov. The company's owners include LUNDBECKFOND INVEST A/S, Novo Holdings A/S and Roche Finance Ltd.. The company has 64 employees (2026). In 2025, the company reported a gross profit of EUR -26,063,175 and a net result of EUR -32,985,370 compared with EUR -32,253,700 the year before. Equity in the 2025 report amounted to EUR 12,410,475.